The company is a high-tech enterprise with Chengdu Polypeptide Pharmaceutical Engineering Technology Research Center. The API and Pharmaceutical Workshop has obtained the GMP certificate, and has undertaken the national 11th Five-Year Plan major new drug development and research projects; API Workshop also passed the FDA on-site GMP inspection with "zero defect" in May 2012.

QQ1
QQ2